JP2008509928A5 - - Google Patents

Download PDF

Info

Publication number
JP2008509928A5
JP2008509928A5 JP2007525838A JP2007525838A JP2008509928A5 JP 2008509928 A5 JP2008509928 A5 JP 2008509928A5 JP 2007525838 A JP2007525838 A JP 2007525838A JP 2007525838 A JP2007525838 A JP 2007525838A JP 2008509928 A5 JP2008509928 A5 JP 2008509928A5
Authority
JP
Japan
Prior art keywords
use according
methylene
tetraazacyclotetradecanyl
phenylenebis
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007525838A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008509928A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/028783 external-priority patent/WO2006020891A2/en
Publication of JP2008509928A publication Critical patent/JP2008509928A/ja
Publication of JP2008509928A5 publication Critical patent/JP2008509928A5/ja
Withdrawn legal-status Critical Current

Links

JP2007525838A 2004-08-13 2005-08-11 前駆/幹細胞を動員するためのケモカインの組み合わせ Withdrawn JP2008509928A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60136704P 2004-08-13 2004-08-13
PCT/US2005/028783 WO2006020891A2 (en) 2004-08-13 2005-08-11 Chemokine combinations to mobilize progenitor/stem cells

Publications (2)

Publication Number Publication Date
JP2008509928A JP2008509928A (ja) 2008-04-03
JP2008509928A5 true JP2008509928A5 (enExample) 2008-10-09

Family

ID=35908186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007525838A Withdrawn JP2008509928A (ja) 2004-08-13 2005-08-11 前駆/幹細胞を動員するためのケモカインの組み合わせ

Country Status (9)

Country Link
US (1) US20060035829A1 (enExample)
EP (1) EP1796716A4 (enExample)
JP (1) JP2008509928A (enExample)
CN (1) CN101094684A (enExample)
AU (1) AU2005272653A1 (enExample)
BR (1) BRPI0514343A (enExample)
CA (1) CA2577046A1 (enExample)
TW (1) TW200608991A (enExample)
WO (1) WO2006020891A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435939B2 (en) * 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
CN101365336B (zh) * 2005-08-19 2013-05-29 健赞股份有限公司 增强化疗的方法
BRPI0621369A2 (pt) * 2006-02-24 2011-12-06 Genzyme Corp uso de compostos que ligam-se ao receptor quimiocina cxcr4 e métodos para aumentar o fluxo de sangue e promover a regeneração do tecido
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
WO2008016006A1 (fr) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
AR063470A1 (es) * 2006-08-02 2009-01-28 Genzyme Corp Terapia combinada
CA2673719C (en) * 2006-12-21 2018-07-24 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
BRPI1009663A2 (pt) 2009-06-14 2016-10-11 Biokine Therapeutics Ltd "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica"
KR20200016407A (ko) 2011-05-16 2020-02-14 젠자임 코포레이션 Cxcr4 길항제의 용도
CN103159690B (zh) * 2011-12-14 2015-03-25 朱靖华 对称大环胺化合物的结晶形式
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
KR102083046B1 (ko) 2012-06-07 2020-02-28 칠드런'스 하스피틀 로스 앤젤레스 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법
CN105431521A (zh) * 2013-02-28 2016-03-23 哈佛学院校长同事会 用于动员干细胞的方法和组合物
US10286039B2 (en) 2014-02-18 2019-05-14 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
WO2016191811A1 (en) * 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
CN111375066B (zh) 2015-07-16 2023-04-25 百欧肯治疗有限公司 治疗癌症的组合物及方法
MX2018010125A (es) 2016-02-23 2019-03-28 Biolinerx Ltd Procedimientos de tratamiento de leucemia mieloide aguda.
WO2017147610A1 (en) * 2016-02-26 2017-08-31 President And Fellows Of Harvard College Highly engraftable hematopoietic stem cells
WO2018085574A2 (en) * 2016-11-02 2018-05-11 Washington University Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof
EP3609890B1 (en) 2017-04-12 2024-09-11 EdiGene Biotechnology, Inc. Aryl hydrocarbon receptor antagonists and uses thereof
US20190343885A1 (en) 2017-10-31 2019-11-14 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
CN111542597A (zh) 2017-10-31 2020-08-14 美真达治疗公司 用于扩增造血干细胞和祖细胞的组合物和方法
AU2018378804B2 (en) 2017-12-06 2025-10-02 Ensoma, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
WO2019136159A1 (en) 2018-01-03 2019-07-11 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
WO2021087406A1 (en) 2019-11-01 2021-05-06 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
IL297690A (en) 2020-04-27 2022-12-01 Magenta Therapeutics Inc Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
EP4308694A1 (en) 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
CN116789639A (zh) * 2022-03-14 2023-09-22 上海医药工业研究院有限公司 Mavorixafor的纯化方法、其盐及有关物质

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
WO1994029341A1 (en) * 1993-06-08 1994-12-22 Smithkline Beecham Corporation Methods of enhancing bioactivity of chemokines
DE4320478B4 (de) * 1993-06-21 2007-11-15 Robert Bosch Gmbh Fahrstabilitätsregler
CA2178902A1 (en) * 1993-12-14 1995-06-22 Drew Pardoll Controlled release of pharmaceutically active substances for immunotherapy
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US6713052B1 (en) * 1995-10-24 2004-03-30 Human Genome Sciences, Inc. Method of mobilizing stem cells with chemokine β-8
EP1016726A1 (en) * 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
HK1046409A1 (zh) * 1999-12-17 2003-01-10 Anormed Inc. 结合趋化因子受体的杂环化合物
KR20030034184A (ko) * 2000-09-15 2003-05-01 아노르메드 인코포레이티드 케모킨 수용체 결합 헤테로사이클릭 화합물
AU9355101A (en) * 2000-09-15 2002-03-26 Anormed Inc Chemokine receptor binding heterocyclic compounds
IL154227A0 (en) * 2000-09-15 2003-07-31 Anormed Inc Chemokine receptor binding heterocyclic compounds
EP2022787B1 (en) * 2000-09-29 2012-11-28 Genzyme Corporation Process for the preparation of N-1 protected N ring nitrogen containing cyclic polyamines and products thereof
CA2443685A1 (en) * 2001-04-03 2002-10-17 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US6987102B2 (en) * 2001-07-31 2006-01-17 Anormed, Inc. Methods to mobilize progenitor/stem cells
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
EP1451297A4 (en) * 2001-12-07 2006-06-28 Toolgen Inc PHENOTYPIC SCANNING OF CHIMERIC PROTEINS
CA2520259A1 (en) * 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
CA2517077C (en) * 2003-04-22 2013-03-12 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
WO2005059107A2 (en) * 2003-12-11 2005-06-30 Anormed Inc. Chemokine receptor binding compounds

Similar Documents

Publication Publication Date Title
JP2008509928A5 (enExample)
US12037321B2 (en) 1,2,4-oxadiazole derivatives as immunomodulators
CA2455559A1 (en) Methods to mobilize progenitor/stem cells
ES2983582T3 (es) Composiciones bioortogonales
JP2014513727A5 (enExample)
JP2008528658A5 (enExample)
JP2008195730A5 (enExample)
JP2017533922A5 (enExample)
JP2014528467A5 (enExample)
JP2011006428A5 (enExample)
CA2361587A1 (en) Methods and compositions to enhance white blood cell count
RU2010113982A (ru) Применение пептида в качестве терапевтического средства
JP2022095872A5 (enExample)
CN101495115A (zh) 组合治疗
RU2006132071A (ru) Производные антраниловой кислоты, способы их получения и применение
US20240158445A1 (en) Cyclic cell-penetrating peptides with three or more hydrophobic residues
RU2014124171A (ru) Лекарственное средство для терапевтического лечения и/или улучшения состояния при сепсисе
CN101175490B (zh) 循环障碍改善剂
EP1345604B1 (en) Use of a alpha-halogen-acryloyl distamycin derivate for the preparation of a medicament for the treatment of cancer
JP2012525391A5 (enExample)
JP2005527479A5 (enExample)
WO2008113095A1 (en) Compositions and therapies comprising tranilast compounds and angiotensin-converting enzyme (ace) inhibitors and/or angiotensin receptor blockers (arb)
CA2954175A1 (en) Compositions and methods to improve adoptive cell therapies
ES2910654T3 (es) Composiciones y métodos para mejorar la migración y el injerto de células madre hematopoyéticas
US20210269482A1 (en) Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same